Vimarsana
Biggest News Aggregation in the World

Page 3 - Genentech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genentech Today - Breaking & Trending Today

Health News Highlights: Drugmaker Under Scrutiny, Bird Flu Outbreak, Diabetes Trials Halted - Vimarsana News

Health News Highlights: Drugmaker Under Scrutiny, Bird Flu Outbreak, Diabetes Trials Halted

Recent health news includes drugmaker WuXi AppTec working with Chinese military scientists on altitude sickness treatments, FDA halting Biomea's diabetes trials due to liver toxicity, and a bird flu outbreak in Minnesota. Additionally, an antitrust probe into pharmaceutical companies over an eye drug and Novo Nordisk facing generic challenges in China are reported.

Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment - Vimarsana News

Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment

By Mary de Wet Relay Therapeutics will collaborate with Pfizer to study atirmociclib in combination with RLY-2608 and fulvestrant in patients with certain types of metastatic breast cancer. ...

Genentech champions health equity initiatives at ASCO 2024 - Vimarsana News

Genentech champions health equity initiatives at ASCO 2024

Genentech sponsored a health equity symposium in partnership with the American Cancer Society and the University of Illinois Cancer Center over the weekend to underscore the need for health equity.

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC - Vimarsana News

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) - Vimarsana News

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...